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Background: The complement cascade not only provides protection from infection but can also mediate
destructive inflammation. Complement is also involved in elimination of neuronal synapses which is essential for
proper development, but can be detrimental during aging and disease. C1q, required for several of these
complement-mediated activities, is present in the neuropil, microglia, and a subset of interneurons in the brain.
Methods: To identify the source(s) of C1q in the brain, the C1qa gene was selectively inactivated in the microglia
or Thy-1+ neurons in both wild type mice and a mouse model of Alzheimer’s disease (AD), and C1q synthesis
assessed by immunohistochemistry, QPCR, and western blot analysis.
Results: While C1q expression in the brain was unaffected after inactivation of C1qa in Thy-1+ neurons, the brains
of C1qaFL/FL:Cx3cr1CreERT2 mice in which C1qa was ablated in microglia were devoid of C1q with the exception of limited
C1q in subsets of interneurons. Surprisingly, this loss of C1q occurred even in the absence of tamoxifen by 1 month of
age, demonstrating that Cre activity is tamoxifen-independent in microglia in Cx3cr1CreERT2/WganJ mice. C1q expression in
C1qaFL/FL: Cx3cr1CreERT2/WganJ mice continued to decline and remained almost completely absent through aging and in
AD model mice. No difference in C1q was detected in the liver or kidney from C1qaFL/FL: Cx3cr1CreERT2/WganJ mice relative
to controls, and C1qaFL/FL: Cx3cr1CreERT2/WganJ mice had minimal, if any, reduction in plasma C1q.
Conclusions: Thus, microglia, but not neurons or peripheral sources, are the dominant source of C1q in the brain. While
demonstrating that the Cx3cr1CreERT2/WganJ deleter cannot be used for adult-induced deletion of genes in microglia, the
model described here enables further investigation of physiological roles of C1q in the brain and identification of
therapeutic targets for the selective control of complement-mediated activities contributing to
neurodegenerative disorders.
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The complement system provides rapid recognition and
response to danger that threatens the host. The comple-
ment cascade is regulated by the local environment [1]
and synergizes with other responses to infection or
stress or both [2–4]. Complement activation is carefully
controlled, and imbalanced activity is associated with* Correspondence: atenner@uci.edu
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ritis, nephritis, traumatic brain injury, and age-related
macular degeneration (reviewed in [5, 6]). The comple-
ment system also functions during development with
complement-dependent synapse pruning being an inte-
gral neurodevelopmental process, at least in the brain
regions such as the retinogeniculate system [7, 8]. While
beneficial during development, recent reports suggest
that unregulated complement-mediated synapse pruning
is associated with behavioral alterations in mouse
models of AD [9], aging [10], frontotemporal dementia
[11], and virus infection [12]. Further delineation of thele is distributed under the terms of the Creative Commons Attribution 4.0
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targeted for therapeutic intervention in such disorders
requires precise information about unintended conse-
quences of inhibition of the entire pathways and clarifica-
tion of the sources of various complement components
that would enable more selective targeting to prevent or
slow neurodegenerative diseases [13].
The complement system consists of over 30 inde-
pendent proteins. C1q is the recognition component
of C1, the classical complement pathway multi-subunit
complex. C1q is a hexamer of trimers composed of three
distinct polypeptide chains, A, B, and C [14], with each
chain required for proper assembly of C1q [15]. When
complexed with C1r and C1s, the enzymatic components
of the C1 complex, C1q binding to an activator initi-
ates a cascade of enzymatic reactions resulting in the
opsonization of the activating substance, generation
of the activation peptides C3a and C5a, and forma-
tion of a membranolytic pore. Binding of C3a and
C5a to their cellular receptors contributes to inflam-
mation [16]. However, C1q, independent of C1r and
C1s, can enhance clearance of apoptotic cells and
cellular debris, downregulate proinflammatory cyto-
kine expression by phagocytes in vitro [17–19], and
protect neurons from nutrient stress and fibrillar
amyloid-induced damage [20, 21] consistent with a
role in maintaining homeostasis. Indeed, synthesis of
C1q is increased in response to a variety of neuronal
injuries (reviewed in [5]).
To analyze the contribution of C1q to Alzheimer’s dis-
ease (AD) pathology, previous studies used a constitutive
C1qa knockout in two mouse models of AD that dem-
onstrated a ~50% decrease in glial activation markers
and protection of neuronal integrity [22]. Subsequent
work treating mouse models of AD with a C5a receptor
antagonist resulted in a 50–70% decrease in pathological
markers suggesting that the detrimental effects of com-
plement activation in the brain were predominantly me-
diated by the proinflammatory C5a fragment generated
upon the activation of the complement cascade through
the cleavage of C5 (to C5a and C5b) [23]. We have pre-
viously shown that C1q synthesis is increased at an early
age in AD mouse models (i.e., in the absence of fibrillar
amyloid plaques), without a similar rise in C1r and C1s,
which are induced only much later when the deposition
of fibrillar amyloid plaques occurs [21]. Thus, with dif-
ferential synthesis of complement proteins in the brain,
C1q could have beneficial effects during neurodevelop-
ment as a component of C1, be directly neuroprotective
early in disease processes independent of other comple-
ment activities, and contribute to complement-mediated
inflammatory events accelerating progression of cogni-
tive loss at later stages of disease, i.e., when C1r, C1s and
other complement pathway proteins are present.To further delineate the physiological roles of C1q in
the brain, including the influence of age, injury, and/or
the cellular source of C1q, new models enabling defined
cellular and temporal control of C1q expression are
needed. Specifically, generation of mice in which C1q is
present for the beneficial and protective activities during
development and early stages of injury, but which could
be ablated at later ages to suppress detrimental activities
resulting from activation of the complement cascade
would be useful. In addition, while there is evidence of
C1q mRNA synthesis in the brain [24–26], the cellular
source of C1q within the brain (neurons or microglia),
and the contribution of the central nervous system
(CNS) versus periphery to the production of functional
C1q protein in the brain with aging and stages of disease
have remained unclear. The ability to regulate detrimen-
tal responses in the brain while retaining the protective
functions of the complement system in the peripheral
would be beneficial particularly for long-term treatment
of chronic diseases. These issues can be investigated
using mice in which Cre recombinase activity can be in-
duced in a time and cell-type specific manner. Here, we
characterized C1q expression in mice homozygous for a
loxP-flanked C1qa chain gene crossed to mice contain-
ing tamoxifen-inducible cre (Cre-ERT2) under control of
the Cx3cr1, Thy1, or Rosa26 promoters. The results,
while revealing a caveat in the use of Cx3cr1CreERT2,
demonstrate that microglia, not neurons or peripheral
sources, are the dominant source of C1q in a healthy
brain at all ages up to 10 months and in an Alzheimer’s
disease transgenic model.
Methods
Generation of mouse models
All animal experimental procedures were approved by
the Institutional Animal Care and Use Committee of
University of California, Irvine, and performed in ac-
cordance with the NIH Guide for the Care and Use of
Laboratory Animals. The C1qatm1a(EUCOMM)Wtsi “re-
porter-tagged insertional with conditional potential”
allele (hereafter referred to as C1qaGT/+) is a gene-trap
allele in which a Frt’d splice-acceptor–lacZ–polyadeny-
lylation (polyA) cassette and PGK-neo/G418 resistance
cassette is inserted within intron 2 of C1qa (see https://
www.mousephenotype.org/data/genes/MGI:88223) (ob-
tained from Jackson Laboratory, Bar Harbor, ME). This
allele is predicted to be null for C1qa function. To
analyze lacZ (β-galactosidase; β-gal) reporter gene ex-
pression from the targeted allele of C1qa, mice with a
C1qaGT/+ allele were crossed with B6.FVB-Tg(Stra8-cre)/
1Reb/LguJ mice (Jackson, stock #017490). This removes
the PGK-neo cassette that is flanked by loxP sites, to
avoid possible interference of the PGK-neo cassette with
transcription of the C1qa-encoded lacZ reporter gene.
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deletion” allele, hereafter referred to as C1qaGT-neo/+, re-
tain one wild type C1qa allele to prevent developmental
abnormalities that may result from a complete deletion of
C1q during development. To generate mice with a cre-
conditional (“floxed”) allele, C1qaGT/+ were crossed with
B6.Cg-Tg(ACTFLPe)9205Dym/J (Jackson, stock # 005703)
mice to produce mice with a C1qatm1c(EUCOMM)Wtsi allele,
hereafter referred to as C1qaFL/+. In the C1qaFL/+ allele,
the coding sequence in exon 3 is flanked by two loxP sites,
one within intron 2 and the other in the 3′ untranslated
region of exon 3. To generate mice for tissue- and
temporal-specific knockout of C1qa, C1qaFL/FL mice were
crossed with B6.129P2(Cg)-Cx3cr1tm2.1(cre/ERT2)Litt/WganJ,
(Jackson, stock #021160) mice, here designated as
Cx3cr1CreERT2/WganJ or Cx3cr1CreERT2, which co-expresses
Cre-ER fusion protein and EYFP in monocytes, dendritic
cells, NK cells, and brain microglia [27], or Tg(Thy1-cre/
ERT2,-EYFP)HGfng/PyngJ, (Jackson, stock #012708), here
referred to as Thy1 CreERT2 which expresses Cre-ERT2
fusion protein and EYFP in Thy1-expressing neurons, or
B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J, (Jackson, stock
#008463), here designated as Rosa26CreERT2 mice which ex-
presses Cre-ERT2 fusion protein ubiquitously. All mice
were on the C57BL6/J background (i.e., Nnt−/−). Progeny
from each cross were backcrossed with C1qaFL/FL mice to
generateC1qaFL/FL:Cx3cr1CreERT2,C1qaFL/FL:Thy1CreERT2, and
C1qaFL/FL:Rosa26CreERT2 animals. In addition, Cx3cr1CreERT2
were crossed to B6;129S6-Gt(ROSA)26Sortm14(CAG-tdTo-
mato)Hze/J (Jackson, stock #007908, also called Ai14(RCL-
tdT)-D), which we refer to as ROSA26-STOP-tdTomato, to
generate ROSA26-STOP-tdTomato +/−: Cx3cr1CreERT2 mice.
As a sensitive cell lineage reporter of Cre activity, cells with a
ROSA26-STOP-tdTomato allele do not express tdTomato
until after the floxed stop cassette has been excised by Cre
recombinase activity. Arctic48 mice were obtained from
Dr. Lennart Mucke (Gladstone Institute, San Francisco, CA,
USA). ConstitutiveC1qa knockoutmice [15] were originally a
gift fromDr.Marina Botto, Imperial College London.
Induction of Cre activity with tamoxifen
Tamoxifen (T5648; Sigma, St. Louis, MO) was dis-
solved in 5% ethanol/corn oil at final concentration of
50 mg/ml. Mice were treated with tamoxifen at
0.2 mg/g body weight or vehicle control by oral gavage
once a day for five consecutive days [28]. Animals were
bled, and tissue was harvested at 3–56 days after treat-
ment as noted.
Collection of tissue
Tissue was processed as previously described [23].
Briefly, mice were anesthetized with isoflurane, perfused
with PBS, and the brains were collected and fixed for
24 h in 4% paraformaldehyde/PBS. To detect C1q ininterneurons, mice were perfused with PBS, followed by
4% paraformaldehyde/PBS for 2 min. Tissue was then
post-fixed for only 2 h in 4% paraformaldehyde/PBS at
4 °C. For some mice, the liver and kidney were also
collected.
Immunohistochemistry
Immunostaining procedures were performed as de-
scribed [22]. Briefly, 40-μm brain or 30-μm liver and
kidney were incubated overnight at 4 °C with primary
antibodies or corresponding control IgG. Primary anti-
bodies were detected with Alexa555 or Alexa488 labeled
secondary antibodies (Invitrogen, Carlsbad, CA). Anti-
bodies used were anti-mouse C1q (rabbit monoclonal,
clone 27.1) tissue culture supernatant (previously gener-
ated and characterized in collaboration with the Barres
lab [29], anti-Cre recombinase (mouse monoclonal
ascites, clone 2D8, 1:1000, Millipore, Temecula, CA),
anti GAD67 clone (mouse monoclonal clone 1G10.2,
1:700, Millipore ), anti-parvalbumin (mouse monoclo-
nal, clone PARV-19, 1:300, Sigma), anti-somatostatin
(rat monoclonal, clone YC7, 1:200, Millipore), anti-F4/
80 (rat monoclonal clone CI:A3-1, 0.5 ug/ml, AbD
Serotec), anti-CD31 (rat monoclonal, clone SZ31, 1 ug/ml,
Dianova, GmbH, Germany), and anti-Iba-1 (rabbit
polyclonal, 1 ug/ml, Wako, Richmond, VA). For coloca-
lization experiments of C1q with other markers, pri-
mary antibodies were incubated simultaneously (with
anti-Cre recombinase, F4/80, CD31, somatostatin, or
parvalbumin) or sequentially (after anti-GAD67) followed
by secondary antibodies. For immunoperoxidase staining
of C1q, CD45 or amyloid ß, sections were pretreated with
3%H2O2/10%MeOH/Tris-buffered saline (TBS), pH 7.4 to
block endoperoxidase. After blocking with 2%BSA/10%
normal goat serum/0.1%Triton/TBS, sections were incu-
bated with anti-mouse CD45 (goat polyclonal 1 ug/ml,
R&D) or anti-amyloid ß (#1536, 1:1,000, gift of Dr. Cooper
[30]) in blocking solution or anti-mouse C1q clone 27.1,
overnight at 4 °C. After incubation with primary antibody,
sections were incubated with the corresponding biotinyl-
ated secondary antibodies (Vector Labs, Burlingame, CA)
(1 h, RT) followed by ABC (Vector Labs) (1 h, RT) and
developed with DAB (3,3′-diaminobenzidine) (Vector
Labs) following manufacturer instructions. Tissue was
dehydrated and mounted with DePeX (BDH Laboratory
Supplies, Poole, England). Immunostaining was analyzed
using a Zeiss Axiovert-200 inverted microscope (Zeiss,
Thornwood, NY) and images acquired with a Zeiss
Axiocam high-resolution digital camera (1300x1030
pixel) using Axiovision 4.6 software. Confocal images
were acquired using a Zeiss LSM 700 or 780 confocal
microscopes and Zen software. Images of staining were
acquired with the same exposure times and camera set-
tings when comparing the same brain area in the different
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(yellow) over total microglia (green + yellow) per animal
was obtained by scoring the number of yellow and green
microglia per field and averaging all five fields per section
(two sections per animal). For quantitative analysis of C1q
in the molecular layer of hippocampus, images were
analyzed using ImageJ software. Four regions of interest
(ROI) (squares) were defined randomly within the mo-
lecular layer area and the mean pixel intensity per ROI
was determined. The mean intensity of each animal
was obtained by averaging all ROI mean intensities in
the sections studied (two–three sections per animal).
For CD45 and Aß, images were analyzed using Axiovision
4.6 sofware. Percentage of immunopositive area (immuno-
positive area/total image area times 100) was determined
by averaging several images per section (n = 2–3 sections
per animal) that covered the hippocampal area. One way
ANOVA statistical analysis was used to assess the
differences in C1q mean intensity, plaque area, and
glial reactivity.ß-gal staining
Detection of lacZ (ß-gal) expression by X-Gal histo-
chemistry was done using a staining kit (Life Technologies,
Carlsbad, CA). Sections were incubated with a final
concentration of 1 mg/ml X-gal, 4 mM potassium
ferricyanide, 4 mM potassium ferrocyanide, and 2 mM
magnesium chloride, with or without 25 μM sodium
deoxycholate at RT or 37 °C for different times (between
30 min and 24 h). Detection of ß-gal by immunostaining
was performed using a rabbit polyclonal anti-ß-galacto-
sidase (0.1–10 ug/ml) (Life Technologies) or chicken
polyclonal anti-ß galactosidase (1:100–1:5000, Abcam,
Cambridge, MA).Microglial isolation, sorting, and immunocytochemistry
Primary neonatal microglia were isolated as described [31]
from postnatal day 2 pups from a C1qaFL/FL:Cx3cr1CreERT2
animal crossed with C1qaFL/FL. Cells were stained with an
Allophycocyanin (APC)-conjugated anti-mouse CD11b.
Viable cells were gated according to size and granularity
(based on forward and side scatter properties), followed
by gates for YFP and CD11b (FACS Aria II). The sorted
populations, (1) YFP+, CD11b+; (2) YFP−, CD11b+; and (3)
YFP−, CD11b−, were plated on poly-L-lysine coated cover-
slips for 1 h. After blocking with 2% BSA/0.1% Triton/PBS
for 30 min and incubating with or without rabbit mono-
clonal anti-C1q antibody (clone 27.1) for 1 h at RT,
followed by Alexa 555 goat anti-rabbit antibody (1 h, RT),
coverslips were mounted with antifade reagent con-
taining DAPI (Prolong gold, Invitrogen). No APC or
Alexa 555 signal was detected when the primary anti-
C1q antibody was omitted.Hemolytic titer
Plasma was collected into EDTA (10 mM final) immedi-
ately preceding perfusions by cardiac puncture. The
blood was withdrawn from the left ventricle with a 25-
gauge needle and transferred to a prechilled glass tube
on ice. After centrifugation at 2000×g for 10 min at 4 °C,
the plasma was removed and immediately distributed
into small aliquots and stored at −80 °C. Two microliters
of mouse plasma diluted in GVB (4.8 mM sodium barbi-
tal, 0.1% gelatin, 142 mM NaCl, 1 mM MgCl2, and
0.15 mM CaCl2 at pH 7.3) was combined with human
C1q-deficient serum (300 μl). Eighty microliters of sheep
erythrocytes (Colorado Serum Co., Denver, CO) previ-
ously sensitized with rabbit anti-sheep erythrocyte im-
munoglobulin (EA) (5 × 108 EA/ml) was added and
incubated at 37 °C for 30 min. After addition of 1.6 ml
ice-cold GVB, reactions were centrifuged at 800×g at 4 °C
for 3 min and the optical density at 412 nm of the super-
natants were obtained as an index of released hemoglobin.
The functional activity of mouse C1q was determined by
analysis of hemolytic activity derived from the means of
duplicate serial dilutions of each sample as previously
described [32].
Western blot
Each frozen half-brain or hippocampus was pulverized,
aliquoted, and stored at −80 °C. Brain powder was
solubilized by homogenization in ten volumes of Tris-
buffered saline (TBS, pH 7.4) containing protease inhibi-
tor cocktail solution (Complete mini, Roche), 1 mM
EDTA, and 2% SDS using motor pestle for 5 s twice on
ice. After centrifugation at 18,400×g for 30 min at 4 °C,
protein concentration in the supernatants was deter-
mined with BCA protein assay (Pierce, Rockford, IL).
Sixty μg of brain protein or 1 ul plasma were subjected
to SDS-polyacrylamide gel electrophoresis (10%) under
reducing conditions. Gels were transferred at 4 °C in
Tris-glycine, SDS, and 10% methanol transfer buffer
onto polyvinylidenedifluoride (PVDF, Immobilon-P,
Millipore) membrane at 300 mA for 2 h. PVDF mem-
brane was blocked 1 h at RT in 5% nonfat dry milk in
TBS-Tween. Rabbit anti-mouse C1q (1151) [33] or
mouse anti-ß-actin (Sigma) in either 5 or 3% milk re-
spectively was applied overnight at 4 °C or 2 h at RT.
After washing, HRP-conjugated secondary antibodies di-
luted 1:5000 (Jackson Labs), were added and incubated
for 1 h at RT. The blots were developed using ECL 2 or
ECL (Pierce) and analyzed using a Nikon D700 digital
camera and the ImageJ software as described [34].
RNA extraction and qRT-PCR
Total RNA from pulverized mouse brain (5–10 mg) was
extracted using the Illustra RNAspin Mini Isolation Kit
(GE Healthcare). cDNA synthesis was performed using
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according to the manufacturer’s protocol. Quantitative
RT-PCR was performed using the iCycler iQ and the
iQ5 software (Bio-Rad) with the maxima SYBR/Green
Master Mix (Thermo Fisher Scientific). The mouse primers
for C1qa [21], C1qb, and C1qc genes [35] and Hprt primers
were obtained from Eurofins MWG Operon (Huntsville,
AL). Hprt primers were designed using primer-blast
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/), with
the forward sequence (5′-3′): AGCCTAAGATGAGCG
CAAGT and reverse sequence (5′-3′): ATCAAAAGTC
TGGGGACGCA. The relative mRNA levels were deter-
mined as follows: mRNA levels = 2-ΔCt and ΔCt = (CtTarget
−CtHPRT). Ct values represent the number of cycles at
which fluorescence signals were detected [36].
Results
C1q in the brain is colocalized with microglia, neuropil,
and interneurons but not Thy1+ neurons.
Initial attempts to use the lacZ reporter detection in
the C1q “reporter-first” gene-targeted mouse failed to
provide a signal in the brain (Additional file 1), and thus,Fig. 1 Expression of C1q is present at normal levels in the brains of C1qaFL
of tamoxifen administration. C1q staining in hippocampus of a WT, b C1qa
C1qaFL/FL, and f C1qaFL/FL:Cx3cr1CreERT2 in the absence of tamoxifen treatmen
6 m) in (a–f). Scale bars: a–c:200 um, d–f: 50 um. g Representative western
and C1qaFL/FL:Cx3cr1CreERT2, run under reducing conditions and probed with
h Densitometric ratio of C1q/ß-actin from several western blots performed
as noted. *P < .03 relative to either WT or C1qFL/FL lacking Cre by one-waythe monoclonal anti-C1q antibody clone 27.1 was used
to analyze C1q expression. As reported [29], this anti-
body stained microglia, interneurons, and was particu-
larly strong in the molecular layer of hippocampus
(Additional file 1: Figure S1A–C). As a negative control
for antibody specificity, tissue from a homozygous
constitutive C1qa knockout animal was routinely stained
in parallel and showed complete lack of reactivity with
this antibody (Additional file 1: Figure S1D).
Before investigating the source of synthesis of C1q
protein in the brain, we first verified that expression of
C1q in mice homozygous for a floxed allele of C1qa
(hereafter referred to as C1qaFL/FL) was unchanged com-
pared to WT using immunofluorescence (Fig. 1a, b, d,
and e) and western blot analysis of whole brain extracts
(Fig. 1g, h). We also verified that Cx3cr1CreERT2WganJ
mice [27] (hereafter called Cx3cr1CreERT2) and Thy1-
CreERT2 [37] mice used to induce cell-specific ablation of
the C1qa gene expressed the CreERT2 fusion protein (as
well as EYFP) as expected in microglia and neurons
respectively in the brain. First, YFP, co-expressed with
CreERT2 under transcriptional control of the Cx3cr1/FL mice but nearly absent in C1qaFL/FL:Cx3cr1CreERT2 mice independent
FL/FL, and c C1qaFL/FL:Cx3cr1CreERT2 mice and in the cortex of d WT, e
t. Representative images of n = 3–4 animals per genotype (ages 3–
blots of total brain protein extract (60 ug per lane) from WT, C1qaFL/FL,
polyclonal anti-mouse C1q (1151) and anti-actin, as a loading control.
as in (g), presented as the means +/− SEM of 4–5 animals per group
ANOVA followed by Bonferroni’s multiple comparisons test
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all Iba1-positive cells (microglia) (Additional file 1:
Figure S2A) as predicted since in the brain, Cx3CR1 is
expressed in all microglia [38], and thus, YFP can be
considered a marker for microglia in this model. In
addition, Cre colocalized with YFP+ cells (microglia) in
Cx3cr1CreERT2 mice (Additional file 1: Figure S2B), as
expected from the construct. Similarly, since Thy1 is a
neuron-specific promoter (present in projection neurons)
Cre and YFP co-label neurons in Thy1CreERT2 mice as
shown in the cortex (Additional file 1: Figure S2C).
We also confirmed that C1q colocalizes with YPF
(Fig. 2a) inside cell bodies of Cx3cr1CreERT2 microglia,
consistent with previous demonstration of C1q coloca-
lization with CX3CR1GFP-positive microglia [29]. In
Thy1CreERT , mice where YFP is expressed in Thy1+ neu-
rons, C1q did not colocalize within YFP+ cells but instead
was detected in the neuropil surrounding YFP-labeled
neurons (Fig. 2b) and in the synaptic layers of the hippo-
campus as previously seen in wild type mice [29]. The
extracellular location of the C1q in these regions was
confirmed by analysis of confocal Z-stack images of C1q
staining in Thy1CreERT2 mice (Additional file 1: Figure S3A).
In the Thy1CreERT2 mice, in addition to microglia, C1q
staining was present in cells that were YFP negative and
that morphologically resembled interneurons (Fig. 2c) and
colocalized with GAD67, an intracellular interneuron-
specific marker (Additional file 1: Figure S3B). Some,
but not all, of the C1q-positive interneurons coloca-
lized with parvalbumin or somatostatin (Additional
file 1: Figure S4).
C1q is unchanged in the brains of C1qFL/FL:Thy1CreERT2
mice treated with tamoxifen, but is significantly reduced
in the brain of C1qFL/FL:Cx3cr1CreERT2 mice even without
tamoxifen treatment.
In animals with the Cx3cr1CreERT2 or Thy1CreERT2, the
fusion protein CreERT2 is Cre fused to a mutant estro-
gen receptor (CreERT2) that binds tamoxifen but not
endogenous estrogen [39]. As a result, the CreERT2 is
predicted to remain in the cytoplasm until exposure to
tamoxifen, at which time the CreERT2 moves into the
nucleus enabling the recombination between loxP sites,Fig. 2 C1q colocalizes with YFP in microglia of Cx3cr1CreERT2 mice but not w
(green) in Cx3cr1CreERT2 mice or b, c YFP (green) in the C1qaFL:Thy1CreERT2 mice.
hippocampus, 9 m. Representative pictures of n = 3–4 animals per genotype.eliminating the intervening DNA sequence. To enable
temporal and cell-specific deletion of the C1qa gene,
Cre deleters were crossed to C1qaFL/FL to generate
C1qaFL/FL:Cx3cr1CreERT2 and C1qaFL/FL control litter-
mates (without Cx3cr1CreERT2) or C1qaFL/FL:Thy1CreERT2
and C1qaFL/FL littermates without Thy1CreERT2. Mice
were treated with tamoxifen to delete C1qa in microglia
or Thy1+ neurons (i.e., C1qaFL/FL:Cx3cr1CreERT2 and
C1qaFL/FL:Thy1CreERT2, respectively). Animals (4–7 m
old) were analyzed between 3–14 days after treatment.
Neither C1qaFL/FL:Thy1CreERT2 nor control C1qaFL/FL
mice showed a decrease in C1q in the brain after tam-
oxifen administration compared with vehicle controls
up to 14 days post treatment by both immunofluores-
cence analyses (Fig. 3a–g) and western blot analysis of
whole brain extracts (Fig. 3h, i).
While analyzing the impact of deleting the C1qa gene
in microglia on total brain C1q protein, C1q staining in
C1qaFL/FL:Cx3cr1CreERT2 adult animals was seen to be
very low or absent, even at the earliest timepoint after
tamoxifen treatment (n = 15, data not shown). Surpris-
ingly, vehicle treated (n = 9, data not shown) and the un-
treated C1qaFL/FL:Cx3cr1CreERT2 animals (Fig. 1c, f ) also
lacked C1q reactivity throughout the brain as shown in
both the molecular layer of the hippocampus (Fig. 1c)
and in the cortex (Fig. 1f ) in contrast to WT (Fig. 1a, d)
or C1qaFL/FL littermate mice (Fig. 1b, e). This dramatic
decline was confirmed by western blot of brain extracts
in 1-and 2-month-old animals (Fig. 1g, h). C1q was
detected in a subset of interneurons (GAD67+) in the
C1qaFL/FL:Cx3cr1CreERT2 mice, although the intensity
was decreased in comparison to interneurons in the
littermates lacking Cx3cr1CreERT2 (Additional file 1:
Figure S4A, right panel).
To determine if the tamoxifen-independent deletion of
C1q in microglia and neuropil was age dependent, the
brain of animals of 1, 1.5, 2, 5, and up to 7 months were
examined for C1q reactivity. By 1 month of age, there
was a profound decrease of C1q in the molecular layer
of hippocampus (Fig. 4e vs a) of C1qaFL/FL:Cx3cr1CreERT2
mice, that further decreased with age (Fig. 4f–i) com-
pared with WT (Fig. 4c, d) or littermate C1qaFL/FLith YFP in Thy1CreERT2 mice. Colocalization of C1q (red) with a YFP
a Cx3cr1CreERT2 8 m, b C1qaFL/+:Thy1CreERT2 CA1, 4 m, c C1qaFL/FL:Thy1CreERT2
Scale bar (a–c): 20 um
Fig. 3 Tamoxifen treatment of C1qaFL/FL:Thy1CreERT2 mice did not change levels of C1q in the brain. C1q reactivity (red) in hippocampus of
untreated (UT) WT (a) and C1qa FL/FL:Thy1CreERT2 (b–f) mice treated with vehicle (b, c) or tamoxifen (d, e, f) for 5 days and perfused at 3,7,or
14 days after treatment. Age 5 m. Scale bar: 50 μm in (a); same magnification in (a–f). Mean intensity of C1q immunofluorescence (g) in the
molecular layer of hippocampus of pictures shown in panels in (a–f). Brain extracts (60 ug per lane) (h) from C1qaFL/FL:Thy1CreERT2 treated with
vehicle (V) or tamoxifen (T) as in (a–f), C1q WT at 5 m, and wild type (WT) plasma (1 ul), were run under reducing conditions and probed with
polyclonal anti-C1q (1151) and anti actin, as a loading control. Densitometric ratio (i) of C1q/ß-actin of blot in (h)
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positive microglia (which remain YFP positive due to the
YFP expressed under Cx3cr1CreERT2) decreased dramatic-
ally by 1–1.5 months of age as seen in the cortex
(Fig. 4j–k) and was essentially negative at all ages thereafter
(Fig. 4l–m) as quantified in Fig. 4n. However, Iba-1-positive
microglia (that are also YFP+, Additional file 1: Figure S2A)
were not reduced in C1qaFL/FL:Cx3cr1CreERT2 (data not
shown). The absence of C1q seen by immunofluorescence
in the brain of C1qFL/FL:Cx3cr1CreERT2 mice was con-
firmed by lack of detection of C1q protein by western
blot (WB) in brain extracts (Fig. 4o). Finally, qRT-PCR
to detect mRNA for the C1qa chain was dramatically
reduced in the brain of both vehicle and tamoxifen treated
C1qaFL/FL:Cx3cr1CreERT2, though not to zero as found in the
brains from constitutive homozygous C1qa knockout mice
(Fig. 4p, top panel). Messenger RNA for the C1qb and C1qc
chains was detected in all animals, including the constitutiveC1qa KO (Fig. 4p), demonstrating the specificity of the re-
combination events.
As complement-mediated synapse pruning has been dem-
onstrated as a normal process in neurodevelopment, it is
important to demonstrate if the C1qa gene is deleted or still
present in neonatal microglia in C1qaFL/FL:Cx3cr1CreERT2
mice to perform this beneficial function. Cells from the
brains of postnatal day 2 litters containing both
C1qaFL/FL:Cx3cr1CreERT2 (YFP+) and C1qaFL/FL (YFP-)
pups were sorted for CD11b (i.e., microglia) and YFP
(indicating the presence of Cre). C1q staining was
clearly detected in both CD11b+ populations (Fig. 4q, r)
with an equal percentage of CD11b+ cells (microglia)
expressing C1q (96%) in YFP+ (C1qaFL/FL:Cx3cr1CreERT2)
and YFP− (C1qaFL/FL) microglia demonstrating that Cre
deletion of the C1qa gene had not yet occurred in micro-
glia from neonatal mice. All CD11b-negative cells lacked
C1q reactivity as expected (Fig. 4s).
Fig. 4 (See legend on next page.)
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Fig. 4 C1q reactivity is present in neonatal microglia of C1qaFL/FL:Cx3cr1CreERT2 pups, but is decreased at 1 month and continues to decline with
age in C1qaFL/FL:Cx3cr1CreERT2. Representative images of C1q immunostaining (red) in the hippocampus (a–h) and cortex (j–m) of C1qFL/FL (a, b),
WT (c, d), or C1qFL/FL:Cx3cr1CreERT2 (e–h, j–m) at different ages as noted in the panels. Identical exposure time and illumination settings were used
for each image in (a–h) and similarly were identical for the images in (j–m). Merged images of C1q immunostaining (red) and YFP (green)
showing C1q colocalization with microglia (yellow, arrows) or progressive lack of C1q (YFP green only, arrowheads) in C1qFL/FLCx3cr1CreERT2 mice
with age (j–m). Average of the mean intensity of C1q immunostaining in the molecular layer (*) of C1qaFL/FL (grasy) or C1qaFL/FL:Cx3cr1CreERT2
(black) at different ages (1 month, n = 4; 1.5 months, n = 1; 2 months, n = 2; 5 months, n = 3; 7 months, n = 2), respectively (i). p values obtained
from data from 3–4 mice at 1 and 5 months by ANOVA single factor analysis are p = 0.02 and 0.005, respectively. Quantification of the percentage
of total microglia that were C1q positive in the cortex of C1qaFL/FL:Cx3cr1CreERT2 mice (n). Percentage of C1q-positive microglia per animal was
obtained by averaging five images per section per mouse. Bar represent average % of C1q-positive microglia in n mice per age (1 month, n = 4;
1.5 months, n = 1; 2 months, n = 2; 5 months, n = 3; 7 months, n = 2). Brain extracts (60 ug per lane) from C1qaFL/FL and C1qaFL/FL:Cx3cr1CreERT2 littermates
at 1 to 7 months of age, C1qKO at 5 m, and wild type (WT) plasma (1 ul) (o), were run as in Fig. 1. Representative of 3–9 animals per genotype. C1qa,
C1qb, and C1qc mRNA relative to Hprt (p) in the brain from C1qaFL/FL (FL), C1qaFL/FL:Cx3cr1CreERT2 at 3, 7, or 14 days after treatment with vehicle (V) or
tamoxifen (T), C1qaKO (KO), and wild type (WT) mice by qPCR. Cells isolated from the brains of 2-day-old C1qaFL/FL:Cx3cr1CreERT2 (YFP+) and C1qaFL/FL
(YFP−) mice were stained with anti-CD11b, sorted by CD11b and YFP and subsequently stained with anti-C1q (red) and DAPI (blue) (q–s). Representative
pictures of microglia (CD11b+) that are (q) Cx3cr1CreERT2 (YFP+) show similar C1q staining compared to (r) C1qaFL/FL (YFP−) microglia (CD11b+). No C1q is
present in populations negative for CD11b and YFP (neurons, astrocytes) (s). Scale bar 100 μm (a–h) or 50 μm (j–m,q–s)
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mice and an Alzheimer’s disease mouse model is also
abrogated in C1qFL/FL:Cx3cr1CreERT2 mice independent of
tamoxifen treatment.
Previous studies have demonstrated that C1q expres-
sion increases with age and with diseases such as
Alzheimer’s disease in both human and mouse models
[26, 29, 40]. To determine whether increased synthesis
of C1q occurs within microglia or other cell types,
mice hemizygous for an AppArctic48 transgene (Arctic+)
that produces a mouse model of Alzheimer’s disease [41, 42]
were used to generate Arctic+: C1qaFL/FL:Cx3cr1CreERT2 and
Arctic+: C1qaFL/FL, C1qaFL/FL:Cx3cr1CreERT2 and C1qaFL/FL
(control) littermates that were aged to 5 and 10 m. Increased
expression of C1q was clearly evident with age and presence
of Arctic transgene in both the hippocampus (Fig. 5a–f)
and cortex (data not shown). In contrast, little to no
C1q was detected in the brains from both Arctic
C1qaFL/FL:Cx3cr1CreERT2 and C1qaFL/FL:Cx3cr1CreERT2
littermates as assessed by immunofluorescence (Fig. 5a, b),
western blot analysis (Fig. 5c, d), and qPCR for C1qa
mRNA expression (Fig. 5e, f). The absence of C1q in the
Arctic:C1qaFL/FL:Cx3cr1CreERT2 model indicates that
the increased C1q expression in Arctic AD mouse
model requires expression of C1q from Cx3cr1 + cells
(i.e., microglia). Total amyloid beta and CD45 levels in
the Arctic mice were not statistically different from Arc-
tic:C1qaFL/FL:Cx3cr1CreERT2 at either 5 or 10 months of age
(Fig. 5g, h), suggesting that in this model the near complete
lack of C1q in the brain does not affect plaque pathology.
C1q in the liver, kidney, and plasma is unaffected in
C1qaFL/FL: Cx3cr1CreERT2 mice.
As some peripheral myeloid populations are known to
express Cx3cr1, the potential contribution of C1q pro-
duced by the liver and kidney or other sources to brain
C1q was investigated. C1q staining in the liver (Fig. 6a)
and kidney (Fig. 6b) from C1qaFL/FL: Cx3cr1CreERT2 andcontrol animals at multiple ages from 1 to 10 months of
age (when brain C1q was barely detectable) showed no
difference in the level of C1q staining relative to WT
(Fig. 6a, b; compare middle with top panels) or to
C1qaFL/FL littermates lacking the Cx3cr1CreERT2 allele
(data not shown). No staining was present in the original
gene trapped (C1qaGT/GT) mice as expected (Fig. 6a, b,
bottom panels), validating the anti C1q antibody specifi-
city in these tissues. Both the liver and kidney from
C1qaFL/FL:Cx3cr1CreERT2 mice showed that C1q colocal-
izes with F4/80 (Additional file 1: Figure S5A, B, respect-
ively), although not all C1q-positive cells were F4/80
positive, consistent with the presence of subsets of mye-
loid cells in the liver [43]. No colocalization of C1q with
the endothelial cell marker CD31 was seen (Additional
file 1: Figure S5C) and confirmed by confocal analysis
(data not shown). While some expression of the highly
photostable GFP protein under transcriptional control of
the Cx3cr1 locus is detected in these tissues [44] (and
data not shown), relatively little if any YFP is detected in
the liver and kidney (Fig. 6c, d vs brain microglia YFP in
Fig. 4), consistent with low to no Cx3cr1-driven CreERT2
[45], the retention of C1qa gene and thus expression of
C1q in these cells.
To determine if the level of C1q in plasma was af-
fected in C1qaFL/FL:Cx3cr1CreERT2 mice, both western
blot analysis of C1q in plasma and hemolytic functional
activity were assessed. C1q hemolytic activity in the
C1qaFL/FL:Cx3cr1CreERT2 mice (untreated, tamoxifen, or
vehicle treated n = 20), which were negative for C1q in
the brain, had only partial, if any, reduction in C1q
plasma levels (data not shown). Plasma C1q protein con-
centration as measured by western blot analysis in
C1qaFL/FL (n = 25) and C1qaFL/FL:Cx3cr1CreERT2 (n = 37)
mice were comparable in range to WT (n = 20) (Fig. 7a).
Western blot analysis of plasma concentrations of C1q
in aged and Arctic (AD model) mice at 5 and 10 months
Fig. 5 C1q reactivity in the hippocampus is nearly absent in AD C1qaFL/FL mouse models crossed to C1qaFL/FL:Cx3cr1CreERT2 mice. a, b C1q
immunostaining (red) in the brains of C1qaFL/FL (left column) and Arctic C1qaFL/FL (right column) without (top row) or with Cx3cr1CreERT2 (bottom
row) at 5 (a) and 10 m (b) of age. Representative images of the molecular layer of 8–10 animals per genotype per age. Acquisition time and
camera gain are identical for each panel within (a or b). The exposure time was shorter in (b) than in (a) to avoid overexposure due to higher
levels of C1q in the Arctic brain at 10 months than at 5 months of age (c and d). Scale bars: 50 um. Western blot analysis for C1q in hippocampal
extracts (60 ug per lane) from C1qaFL/FL, Arctic:C1qaFL/FL, C1qaFL/FL:Cx3cr1CreERT2 and Arctic:C1qaFL/FL:Cx3cr1CreERT2 at c 5 and d 10 months of age.
Representative of 4 animals per genotype per age. e, f Increased C1qa mRNA expression relative to Hprt in hippocampal extracts from Arctic
compared C1qaFL/FL, mice at both e 5 months and f 10 months, with almost complete absence in all animals containing C1qaFL/FL:Cx3cr1CreERT2.
Representative of 2–4 animals per genotype for 5mo and 3 animals per genotype for 10mo old mice. g Quantification (% Field Area) of amyloid
and h CD45 staining in Arctic C1qaFL/FL with and without Cx3cr1CreERT2 at 5 (left) and 10 (right) months of age. n = 8–10 mice per genotype per
age. Not statistically different by genotype at each age as assessed by one-way ANOVA (CD45 p = 0.10 (5 months) and p = 0.9 (10 months);
Aß p = 0.8 (5 months) and p = 0.95 (10 months)
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Fig. 6 No overt difference in expression of C1q in liver cells and kidney macrophages in C1qaFL/FL:Cx3cr1CreERT2 compared to wild type mice,
correlating with lack of YFP/Cre expression in these tissues in C1qaFL/FL:Cx3cr1CreERT2. C1q staining of the liver (a) or kidney (b) WT (top panels),
C1qaFL/FL:Cx3cr1CreERT2 (middle panels). C1q reactivity is absent from C1qGT/GT (bottom panels) as expected demonstrating specificity of the antibody
in these tissues. Representative pictures of n = 2–5 mice per genotype per age at 4–6 months. C1q (red) but not YFP (green) is detected in the
liver (c) and kidney (d) of Cx3cr1CreERT2 mice (4 months). Bottom panels of (c and d) are the merged images of C1q and YFP. Scale bars: 50 um
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of the C1qaFL/FL:Cx3cr1CreERT2 (Fig. 7b). All C1qFl/FL mice
crossed to Thy1CreERT2 (with or without tamoxifen
treatment) mice reflected the same range of plasma
C1q concentrations as littermate controls lacking the
Cre construct (data not shown). In all cases tested, rela-
tive levels of hemolytic activity matched the protein
levels determined by western blot. These data demon-
strate that the C1q protein in the uninjured brain, aged
brain, or brain stressed by the presence of amyloid
plaque and microglial activation is not derived from the
blood, but rather from CX3CR1 expressing cells within
the CNS itself (i.e., microglia).
Cre activity from the Cx3cr1CreERT2 allele is “leaky” in
the absence of tamoxifen in long-lived microglia.
Similar to the Thy1CreERT2 mice, C1qaFL/FL mice crossed
to RosaCreERT2 (ubiquitously expressed Cre-ERT2) had no
difference in the level of C1q in the brain in the absence of
tamoxifen at any ages tested (2–6 m). Importantly, C1q was
reduced in the brain after tamoxifen treatment of C1qaFL/FL:
RosaCreERT2/+ mice (Additional file 1: Figure S6). These
results suggest the robust CreERT2 expression driven by the
Cx3cr1 promoter compared to the relatively weak promoterof the Rosa26 locus that is responsible for the tamoxifen-
independent gene deletion, and not an inherent property of
C1qaFL/FL. To further test this prediction, we looked for evi-
dence of Cx3cr1CreERT2-mediated loxP recombination using
mice containing a different floxed sequence. The ROSA26-
STOP-tdTomato allele has a “floxed” stop cassette upstream
of a coding sequence for tdTomato, such that cells express
tdTomato only after the stop cassette has been removed by
Cre activity. Tamoxifen-independent tdTomato fluorescence
was observed in microglia in ROSA26-STOP-tdTomato
crossed to Cx3cr1CreERT2 mice by 1 and 2 months of age,
consistent with leakage of the recombinase activity to the
nucleus in these cells (Additional file 1: Figure S7). The per-
centage of YFP-positive cells that were also tdTomato-
positive cells was 60.15% +/−SE 2.6 (n = 2) at 1 month and
73.6%, +/−SE 0.9 (n = 2) at 2 months, compared to 0% of
Rosa26-STOP-tdTomato mice littermate controls lacking
the Cx3cr1CreERT2. Together, these results demonstrate that
the tamoxifen-independent recombination of loxP sites me-
diated by the Cx3cr1CreERT2 allele is not specific to the C1qa
gene, and that this Cx3cr1CreERT2, but not all CreERT2 deleter
mice show C1q gene ablation in microglia in the absence of
the inducer tamoxifen. That is, Cx3cr1CreERT2WgaJn is “leaky”,
Fig. 7 C1q concentration is similar in the blood of C1qaFL/FL:Cx3cr1CreERT2 and C1qaFL/FL littermates lacking Cx3cr1CreERT2. a Compiled densitometry
of western blot analysis of plasma (1 ul loaded per lane under reducing conditions) from a total of 82 animals: C1qaFL/FL:Cx3cr1CreERT2 (dotted line,
N = 5, 5, 8, and 19), C1qaFL/FL littermates (solid line, N = 3, 4, 8, and 10), and C57BL6/J (dashed line, N = 2, 5, 10, and 3). Plotted values for 4 and
8 months are pooled data from 3–5 and 7–10 months of age, respectively. Membranes were probed with rabbit anti-mouse C1q antibody (1151).
Values are +/− SEM. Concentration was determined relative to known wild type plasma C1q concentration on each gel. No significant difference
was observed between the groups by one-way ANOVA followed by Bonferroni’s multiple comparisons test (GraphPad). b The same analysis was
performed for 5 months (gray) and 10 months (black) C57BL6/J, C1qaFL/FL, Arctic C1qaFL/FL, C1qaFL/FL:Cx3cr1CreERT2, and Arctic:C1qaFL/FL:Cx3cr1CreERT2,
all in the absence of tamoxifen treatment. There are no statistical differences in plasma C1q concentration among these ages and genotypes,
using one-way ANOVA with Bonferroni’s multiple comparisons test
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of tamoxifen, which compromises its use in studies
involving postnatal temporal induction of Cre deletion
of floxed genes.
Discussion
Cell-specific Cre-recombinase-mediated ablation of the
C1qa gene was used to demonstrate that microglia, but
not Thy1+ neurons or peripheral blood, are the domin-
ant source of C1q in mouse brain beyond one month of
age. The data also indicate that the enhanced expression
of C1q with aging and as seen in AD models is also pre-
dominantly, if not exclusively, microglial. Upon deletion
of microglial C1qa, C1q is only detected at very low
levels in subpopulations of interneurons in the brain.
Given the known functions of C1q in clearing apoptotic
cells while suppressing proinflammatory cytokine pro-
duction (reviewed in [46]) and signaling direct neuropro-
tection [21], a dominant microglial synthesis of C1q is
consistent with a reparative and protective role for
microglia and the importance of an anti-inflammatory
environment to maintain normal brain function. Yet,
when infection or damage increases such that other
complement proteins are produced, as occurs in neuro-
degenerative diseases, more powerful effector mecha-
nisms can be enabled, including activation of the
complement cascade with potential collateral progressive
inflammatory polarization of microglia with damaging
consequences.
The site of synthesis of complement proteins was trad-
itionally believed to be in the myeloid compartment ofthe liver [47]. Petry and colleagues demonstrated that
wild type bone marrow transplanted into a constitutive
C1q knockout mouse could completely restore the
plasma compartment of C1q [48]. However, in the past
two decades there have been multiple reports of in-
creases in C1q synthesis upon injury, particularly in the
nervous system (reviewed in [49]) but also in other
tissues [50, 51]. The upregulation of mRNA for comple-
ment components in the brain with age and in neurode-
generative diseases such as AD has been documented in
both human [26, 52] and mouse models [53, 54] of
disease. Evidence for both microglial and neuronal synthesis
have been presented [7, 24, 55, 56]. Here, when C1qaFL/FL
mice were crossed with animals expressing CreERT2 under
control of the Cx3cr1 locus (Cx3cr1CreERT2), within 1 month
of age, most of the brain C1q was eliminated, while no
alteration in C1q protein was detected in the brain
after tamoxifen treatment of mice containing a trans-
gene expressing a tamoxifen-inducible CreERT2 under
the neuronal Thy1 promoter.
Surprisingly, the deletion of the C1qa gene in C1qaFL/FL:
Cx3cr1CreERT2 mice occurred even in the absence of the
tamoxifen suggesting that the CreERT2 gains access to the
nucleus independently of tamoxifen to cause the deletion.
Similar tamoxifen-independent Cre-recombinase activity
was demonstrated with a different floxed sequence in
microglia from ROSA26-STOP-tdTomato:Cx3cr1CreERT2
(Additional file 1: Figure S7). Thus, these data suggest that
the Cx3cr1CreERT2WganJ mouse does not maintain normal
expression of floxed genes in microglia in the absence of
tamoxifen, thereby limiting its use for inducible deletion
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Cx3cr1-driven Cre deleter investigated only young
Cx3cr1CreERT2 mice treated with tamoxifen [27].
Importantly, in peripheral tissue macrophages and Kupffer
cells with a shorter lifespan and lower Cx3cr1 expression, re-
duction of C1q expression was not detected. In addition,
microglia in C1qaFL/FL mice that also had the ubiquitously
expressed Rosa26CreERT2 allele also did not show a decrease
in C1q in the absence of tamoxifen suggesting that in con-
trast to Cx3cr1CreERT2, the level of expressed CreERT2 under
control of the Rosa26 promoter does not result in sub-
stantial entry of the recombinase into the nucleus to result
in a detectable reduction of C1q. We hypothesize that the
greater longevity of microglia combined with the promin-
ent expression of CX3CR1 in microglia enables sufficient
CreERT2 to enter the nucleus of these cells, deleting the
floxed C1qa gene, thereby abrogating synthesis of C1q in
those cells permanently. As the animals age, without turn-
over/renewal of this long-lived microglial population, cells
with the deleted floxed gene will accumulate abrogating
specific protein expression. Similar “leakiness” of a dif-
ferent inducible CreERT under the robust GFAP promoter
has been reported in Bergmann glial cells [57]. Thus,
while microglia-specific gene ablation was achieved, tem-
poral regulation of C1q synthesis could not be controlled
by proposed inducible Cx3cr1CreERT2 due to tamoxifen-
independent Cre-dependent ablation in these cells within
a few weeks of birth. Table 1 summarizes the effects of
different inducible CreERT2 tested here.
Interestingly, recent studies have shown that activation
of the C1 complex results in the covalent tagging of
synapses with the activation fragments C3b and iC3b,
marking them for elimination by microglia via the com-
plement receptor CR3 [8]. While initially discovered as
critical for proper brain development (reviewed in [58]),
overzealous or inappropriate “pruning” of synapses has
now been associated with loss of function or alterationsTable 1 Effect of Promoter Specific CreERT2 Expression
Model Target Gene Cre construct Tamoxifena
C57Bl6J C1qa Thy1 CreERT2 -
+
C57Bl6J C1qa Cx3cr1CreERT2/WganJ -
+
C57Bl6J C1qa Rosa26CreERT2 -
+
Arctic C1qa Cx3cr1CreERT2/WganJ -
C57Bl6J CAG-tdTomato Cx3cr1CreERT2/WganJ -
a"-" indicates no treatment, "+" indicates Tamoxifen treatment as described in Mate
b"-" indicates no change from wild type control and arrow down indicates decreas
cevidence of nuclear recombinase activityin behavior in mouse models of frontotemporal demen-
tia [11], epilepsy [59], AD [9], and West Nile Virus infec-
tion [12]. However, it is also well supported that the
activation of the complement cascade can lead to the
generation of C5a which can recruit glia, promote their
proinflammatory polarization (reviewed in [49]), and
could also be a cause of the loss of phenotypic functions
[23] noted in these systems. Future studies will be
important to determine the relative contribution of the
increased synapse elimination versus complement activa-
tion leading to C5a-enhanced inflammation/injury to
these behavioral impairments. In addition, since evidence
of localized neuronal C1q has been reported, it remains to
be tested if specific deletion of microglial C1q will abro-
gate complement-dependent synapse pruning or if local
synthesis of C1q may be induced in neurons during de-
velopment, infection or other disease states which we
did not assess here, with physiological consequences.
Conclusions
The data presented here show that microglia, not peripheral
blood or other CNS cells, are the overwhelming source of
C1q in the murine brain from postnatal through the aging
adult (at least though 10 months of age) and in one mouse
model of Alzheimer’s disease, where C1q levels are nor-
mally dramatically increased with age and amyloid accumu-
lation. Although these data demonstrate that loss of C1q in
microglia occurs after 1 month of age with the
Cx3cr1CreERT2/WganJ strain [27] independent of tamoxifen
and thus temporal induction is not possible, this cell-
specific deleter strain of mice may be valuable to determine
if the cellular source of C1q (and indeed any microglia-
expressed gene) in vivo changes in various models of neuro-
logical disorders and will enable subsequent investigation of
the beneficial or detrimental contribution of CNS C1q to
the progression of neurodegenerative diseases, including
cognitive decline. We also show that it is possible to depleteEffect on target gene expressionb
IHC Western blot QPCR Titer
Brain Liver Kidney Brain Blood Brain Blood
- - - -
- - - -
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blood, thus enabling the delineation of C1q-mediated
events as being of CNS rather than peripheral origin. These
results provide a characterized framework for further inves-
tigation of beneficial roles as well as detrimental effects of
complement in the CNS (reviewed in [60]), clarification of
the contribution of peripheral complement to neurodegen-
erative diseases [13, 61], determination of what controls the
induction of C1q synthesis in the brain, and subsequent de-
sign of selective and specific therapeutic interventions for
complement-mediated events in neurodegenerative diseases
[62].
Additional file
Additional file 1: Failure to detect lacZ activity in the C1q “reporter-first”
gene-targeted mouse, C1qatm1a(EUCOMM)Wtsi. (DOCX 3 mb)
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